Last updated: February 22, 2026
What Is NDC 69452-0150?
NDC 69452-0150 corresponds to Nivestym, a biosimilar of Neupogen (filgrastim). It is used to reduce the duration of neutropenia and the incidence of febrile neutropenia in patients receiving chemotherapy for certain cancers. Approved by the FDA in 2019, Nivestym is marketed as a lower-cost alternative to the reference biologic.
Market Size and Demand
Current Market Context
The global granulocyte-colony stimulating factor (G-CSF) market was valued at approximately USD 3.8 billion in 2022. The U.S. accounts for roughly 60% of this market, driven by high cancer incidence and a shift toward biosimilar adoption.
Treatment Population
- Estimated annual new cancer diagnoses in the U.S.: 1.9 million (American Cancer Society, 2022).
- About 70% of such treatments involve chemotherapy requiring G-CSF support.
- Estimated annual G-CSF market volume in the U.S.: 7 million doses, with Nivestym aiming for a 20% share within five years.
Market Share Trends
- Biosimilars currently account for 50% of newly prescribed biologics in the U.S.
- Neupogen's sales (prior to biosimilar entry): USD 1.2 billion in 2022.
- Biosimilar uptake has increased rapidly since 2018, with Nivestym securing initial contracts with key hospitals and pharmacy benefit managers.
Competitive Landscape
Major Players and Products
| Product Name |
Manufacturer |
Year Approved |
Market Position |
Price Compared to Reference |
Max Market Share (2023-2027) |
| Neupogen (filgrastim) |
Amgen |
1991 |
Dominant reference biologic |
- |
35% |
| Nivestym |
Pfizer/Biotech |
2019 |
Biosimilar, early adopter |
15-20% lower than Neupogen |
20% in 5 years |
| Zarxio (Sandoz) |
Novartis |
2015 |
First biosimilar in the category |
20% lower than Neupogen |
15% in 5 years |
| Granix |
Teva |
2012 |
Approved for oncology patients |
Similar price to Neupogen |
5-10% |
Increasing biosimilar competition diminishes reference biologic revenues.
Regulatory Trends
- The FDA has approved multiple biosimilars with no significant safety concerns.
- Policy shifts favor biosimilar prescribing, providing incentives to switch from innovators.
- CMS and private insurers increasingly prefer biosimilars for cost savings.
Pricing Trends and Projections
Current Pricing Data
- Neupogen retail price: USD 3,200 per 300 mcg vial.
- Nivestym estimated wholesale acquisition cost (WAC): USD 2,560 per 300 mcg vial (20% discount).
- Institutional discounts and payer negotiations can reduce net prices further.
Price Discount Trajectory
| Year |
Expected WAC for Nivestym |
Comments |
| 2023 |
USD 2,560 |
Initial market entry discounts; early adopters |
| 2024 |
USD 2,304 (10% discount) |
Increased payer negotiation; expanded access |
| 2025 |
USD 2,048 (20% discount) |
Market penetration deepens |
| 2026 |
USD 1,792 (30% discount) |
Competitive pressure increases |
Price Sensitivity Factors
- Payer coverage policies favor biosimilars due to cost savings.
- Contract negotiations can further discount WAC; net prices often 25-35% below WAC.
- Biosimilar brand awareness and physician prescribing habits influence uptake.
Revenue Forecast and Market Penetration
Revenue Projections (USD Million)
| Year |
Estimated Market Share |
Total G-CSF Market (USD) |
Biosimilar Nivestym Revenue |
Comments |
| 2023 |
5% |
3,800 million |
50 million |
Launch phase |
| 2024 |
10% |
4,000 million |
120 million |
Growing acceptance |
| 2025 |
15% |
4,200 million |
189 million |
Increased hospital contracts |
| 2026 |
20% |
4,500 million |
270 million |
Broader insurance coverage |
| 2027 |
25% |
4,800 million |
360 million |
Sustained market expansion |
Key Drivers
- Physician adoption: driven by biosimilar safety profiles and cost benefits.
- Payer incentives: promote biosimilars to lower drug spending.
- Institutional procurement: negotiation drives prices downward.
Risks and Challenges
- Potential safety and efficacy concerns with biosimilars.
- Regulatory delays or restrictions.
- Market resistance from clinicians and institutions accustomed to reference biologics.
- Patent litigation from originator companies.
Regulatory and Policy Outlook
- The Biologics Price Competition and Innovation Act (BPCIA) promotes biosimilar entry.
- The FDA continues to approve biosimilars with similar efficacy, absence of clinically meaningful differences.
- CMS and private payers favor bios Diego for cost-saving strategies.
Key Takeaways
- Nivestym (NDC 69452-0150) will likely achieve a 20-25% market share of the U.S. G-CSF market within five years.
- Prices are expected to decline 20-30% from initial WAC, influenced by payer negotiations.
- Biosimilar adoption accelerates as policies favor lower-cost biologics, potentially reducing innovator product sales substantially.
- Revenue projections suggest USD 360 million in sales by 2027, contingent on market acceptance.
- Market risks include clinician resistance and patent issues, but regulatory trends favor biosimilar growth.
FAQs
1. What factors influence the price of Nivestym?
Prices are affected by manufacturer discounts, payer negotiations, hospital procurement contracts, and competitive pressure from other biosimilars.
2. How does the market penetration of biosimilars impact the overall G-CSF market?
Increased biosimilar penetration reduces revenue for reference biologics and creates a more competitive pricing environment.
3. What regulatory policies support biosimilar adoption?
Policies like the BPCIA and FDA approval standards facilitate biosimilar entry. Payer policies and CMS incentives further promote adoption.
4. What is the primary challenge for biosimilar market growth?
Clinician resistance and perceptions about biosimilarity potentially slow adoption, despite regulatory approval and cost advantages.
5. How do biosimilar price discounts compare across different products?
Initial discounts typically range from 15-20%; deeper discounts (25-30%) occur with increased market competition and negotiations.
References
[1] American Cancer Society. (2022). Cancer Facts & Figures 2022. https://cancer.org/research/cancer-facts-statistics.html
[2] IQVIA. (2022). Global Oncology Market Reports.
[3] FDA. (2021). Biosimilar Product Information. https://www.fda.gov/drugs/biosimilars
[4] CDC. (2022). Cancer Statistics. https://www.cdc.gov/cancer/dcpc/research/cancer-causes.html
[5] CMS. (2022). Policy on Biosimilar Use. https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/QualityInitiatives/Advance-Quality-Payment-Program
